Latest Headlines

Latest Headlines

EMA warns of PML, cancer risks from Novartis' Gilenya

Earlier this year, U.S. regulators updated the label of Novartis' multiple sclerosis pill, Gilenya, to reflect cases of serious brain infections linked to the treatment. And now, its counterparts across the pond are following suit.

Biogen, Sanofi, Novartis tout long-term benefits at ECTRIMS as new competition advances

Biogen, Sanofi and Novartis are all touting new data showing long-term benefits for their respective meds at this year's European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting--and with tough new competition on the way, they may need it.

Early Gilenya generics now spell trouble for rival MS drugs

Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis multiple sclerosis drug in line for early generic competition.

FDA updates label for Novartis' MS pill Gilenya after reports of brain infection

Novartis is dealing with more regulatory pushback on its MS med Gilenya as the agency said it will update Gilenya's label to reflect cases of serious brain infections linked to the pill.

Biogen's hot MS meds could push Pfizer off its CNS throne

Pfizer is still king of the CNS hill, bringing in sales that top its Big Pharma rivals. But the company could soon face some competition at the top, as Biogen moves in with promising sales for its multiple sclerosis drugs, according to a report from GlobalData prepared for PMLiVE.

PhIII failure dashes Novartis' hopes of Gilenya label expansion

Novartis is looking to expand sales of oral multiple sclerosis therapy Gilenya, which currently trails Biogen Idec pill Tecfidera in the MS arena despite its first-to-market advantage. But it looks like it won't be doing that with a primary progressive MS indication anytime soon.

Novartis MS drug Gilenya could relieve painful side effect of chemo

Novartis' multiple sclerosis drug Gilenya may be able to mitigate a painful side effect of chemotherapy in cancer patients, according to a new preclinical study.

Novartis sees brain-atrophy data as an edge for MS pill Gilenya

Fresh off winning European backing for broader use--which could prompt more multiple sclerosis patients to switch--Gilenya's ability to protect patients' brains is at center stage at this week's American Academy of Neurology meeting.

Novartis, Biogen Idec release more strong data on hot-selling MS pills

The day after showing that two of their respective therapies provided better results with earlier treatments, the companies followed up with analyses of safety and brain volume loss for their oral drugs, both of which have already gained significant market share in treating the disease.

Top 15 Drug Launch Superstars

Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>